[Extracorporeal antiaggregant pharmacotherapy in the treatment of acutely progressive forms of tuberculosis].
The investigation was undertaken to study whether extracorporeal pharmacotherapy with the antiaggregant pentoxiphylline (trental) might be used to correct blood rheological disorders in the early combined treatment of 32 patients with acutely progressive destructive tuberculosis, including 15 patients with caseous pneumonia. The method is based on the administration of in vitro drug-treated autologous blood cells. Two-three-week extracorporeal pharmacotherapy with the antiaggregant pentoxiphylline substantially improved pulmonary microcirculation and made the laboratory values of hypercoagulation and endotoxicosis better. The method promoted accelerated regression of the clinical and X-ray manifestations of the disease in 27 of the 32 patients. Few observations lead to a preliminary conclusion that this method positively affects the results of treatment for acutely progressive forms of tuberculosis, including those of treatment for caseous pneumonia.
Kibrik
B S
BS
Chelnokova
O G
OG
D000995:Antitubercular Agents / Q000627:therapeutic use; D001774:Blood Chemical Analysis; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D007275:Injections, Intravenous; D010431:Pentoxifylline / Q000008:administration & dosage / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D010975:Platelet Aggregation Inhibitors; D010431:Pentoxifylline